All In Biotech

Drug Trial Radar · NCT06643884

Suprachoroidal Administration in Subjects With Metastases to the Choroid

A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 16, 2024

Primary completion

Nov 30, 2026

Study completion Oct 31, 2027

Sponsor

Lead sponsor
Aura BiosciencesIndustry
Sponsor type
Industry
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.

Conditions

  • Eye Cancer
  • Primary Cancer

Interventions

  • AU-011Drug

    AU-011 Via Suprachoroidal Administration with laser treatment

  • SCS MicroinjectorDevice

    Suprachoroidal Injection Device

  • LaserDevice

    Laser Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in choroidal tumor thickness on B-scan ultrasonography (B-scan) 4 weeks after completion of treatment.Time frame: 4 weeks after completion of treatment
  2. Change from baseline in choroidal tumor largest basal diameter (LBD) on fundus photos 4 weeks after completion of treatment.Time frame: 4 weeks after completion of treatment

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Byers Eye Institute at Stanford University

    Palo Alto, California · Recruiting

  • Bascom Palmer Eye Institute

    Miami, Florida · Recruiting

  • Massachusetts Eye and Ear

    Boston, Massachusetts · Recruiting

  • Kellogg Eye Center

    Ann Arbor, Michigan · Recruiting

  • Associated Retinal Consultants (ARC) PC

    Royal Oak, Michigan · Not yet recruiting

  • Mayo Clinic

    Rochester, Minnesota · Not yet recruiting

  • Cleveland Clinic, Cole Eye Institute

    Cleveland, Ohio · Recruiting

  • OH State Wexner Medical Center, Havener Eye Institute

    Columbus, Ohio · Not yet recruiting

  • Retina Consultants of Oklahoma

    Oklahoma City, Oklahoma · Not yet recruiting

  • Tennessee Retina, PC

    Nashville, Tennessee · Recruiting

  • Retina Consultants of Texas

    Bellaire, Texas · Recruiting

  • Texas Retina Associates

    Dallas, Texas · Not yet recruiting

  • University of Washington

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.